Tumour Growth Rate as a validated early radiological biomarker able to reflect treatment-induced changes in Neuroendocrine Tumours; the GREPONET-2 study.
CONCLUSIONS: TGR has a role as biomarker for monitoring response to therapy for early prediction of PFS and radiological objective response.
PMID: 31375514 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Lamarca A, Ronot M, Moalla S, Crona J, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvalho LFDP, Bezerra ROF, Borg P, Vietti Violi N, Vidal Trueba H, de Mestier L, Schaefer N, Baudin E, Sundin A, Costa FP, Pavel M, Dromain C Tags: Clin Cancer Res Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | CT Scan | MRI Scan | Neurology | Pancreas | Pancreatic Cancer | Study